Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy
Using a novel genetic ‘editing’ technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.
Instead of the common gene therapy approach of adding new genetic material to “override” the faulty gene, the Duke scientists have developed a way to change the existing mutated gene responsible for the disorder into a normally functioning gene. The Duke researchers believe their approach could be safer and more stable than current methods of gene therapy.
The researchers are now conducting further tests of this new approach in animal models of the disease.
Duchenne muscular dystrophy is a genetic disease affecting one in 3,600 newborn males. The genetic mutation is found on the X chromosome, of which males have only one copy. (Females, with two X chromosomes, presumably have at least one good copy of the gene.)
Patients with Duchenne muscular dystrophy cannot produce the protein known as dystrophin, which is essential in maintaining the structural integrity of muscle fibers. Over time, patients with the disorder suffer gradual muscle deterioration, which leads to paralysis and eventual death, usually by age 25.
“Conventional genetic approaches to treating the disease involve adding normal genes to compensate for the mutated genes,” said Charles Gersbach, assistant professor of biomedical engineering at Duke’s Pratt School of Engineering and Department of Orthopaedic Surgery and member of Duke’s Institute for Genome Sciences and Policy. “However, this can cause other unforeseen problems, or the beneficial effect does not always last very long.
“Our approach actually repairs the faulty gene, which is a lot simpler,” said David Ousterout, the Duke biomedical engineering graduate student in the Gersbach lab who led the work. “It finds the faulty gene, and fixes it so it can start producing a functional protein again.”
The results of the Duke study were published online in Molecular Therapy, the journal of the American Society for Gene and Cell Therapy. The project was supported by the Hartwell Foundation, the March of Dimes Foundation and the National Institutes of Health.
The Duke experiments, which were carried out in cell samples from Duchenne muscular dystrophy patients, were made possible by using a new technology for building synthetic proteins known as transcription activator-like effector nucleases (TALENs), which are artificial enzymes that can be engineered to bind to and modify almost any gene sequence.
These TALENs bind to the defective gene, and can correct the mutation to create a normally functioning gene.
“There is currently no effective treatment for this disease,” Gersbach said. “Patients usually are in a wheelchair by the age of ten and many die in their late teens or early twenties.”
Duchenne muscular dystrophy has been extensively studied by scientists, and it is believed that more than 60 percent of patients with this type of mutation can be treated with this novel genetic approach.
The Latest Bing News on:
Duchenne muscular dystrophy
- Manalapan Dad To Walk From D.C. To NJ For Son With Rare Diseaseon October 13, 2020 at 2:17 pm
"The doctors told us … just love him until he passes, but that's not something I can accept. I choose to fight every day for him." ...
- Ridgefield boy, battling disease, becomes a focus during Supreme Court open seat hearingon October 13, 2020 at 9:30 am
As two Ridgefield families battle Duchenne muscular dystrophy, Senator Blumenthal raises ObamaCare protections in Senate hearing on Judge Barrett.
- NJ dad walking D.C. to Old Bridge to spotlight illness that could kill sonon October 12, 2020 at 2:24 am
JAR of Hope continues to raise awareness of Duchenne muscular dystrophy, an affliction that affects some 20,000 boys in New Jersey and is ultimately fatal.
- New drug to treat muscular dystrophy based on U of A researchon October 11, 2020 at 4:58 am
A University of Alberta researcher’s past work has led to a new drug being approved for use in the United States to treat patients suffering from Duchenne muscular dystrophy (DMD). The drug, ...
- FDA approves new drug to treat common form of muscular dystrophy based on research from U of A scientiston October 9, 2020 at 5:15 am
A University of Alberta researcher's past work has led to a new drug being approved for use in the United States to treat patients suffering from Duchenne muscular dystrophy (DMD).
- New Documentary Follows Family After Sons' Muscular Dystrophy Diagnosison October 8, 2020 at 2:34 pm
What happened: A rare form of muscular dystrophy is chronicled in a new documentary where director and father Nick Taussig navigates the family’s life after his two sons are diagnosed with the ...
- Amber Specialty Pharmacy Selected by PTC Therapeutics, Inc. to Dispense EMFLAZA® for Duchenne Muscular Dystrophy Patientson October 8, 2020 at 1:50 pm
Amber Specialty Pharmacy announces that it will begin dispensing EMFLAZA® (deflazacort) to patients throughout the United States. EMFLAZA is manufactured by PTC Therapeutics, Inc., headquartered in ...
- Santhera halts trial of DMD drug Puldysa, launches revampon October 6, 2020 at 3:23 am
Santhera Pharmaceuticals has halted a late-stage clinical trial of Puldysa (idebenone) in patients with Duchenne muscular dystrophy (DMD) after data from an interim analysis concluded the study was ...
- Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamoroloneon October 5, 2020 at 10:19 pm
Stock quotes by finanzen.net Santhera will hold a conference call today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, October 6, 2020 – Santhera ...
- Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular ...on October 5, 2020 at 10:00 pm
Santhera Pharmaceuticals (SIX: SANN) announces the discontinuation of its Phase 3 SIDEROS study with Puldysa® (idebenone) in patients with Duchenne muscular dystrophy (DMD) who are in respiratory ...
The Latest Google Headlines on:
Duchenne muscular dystrophy
The Latest Bing News on:
Transcription activator-like effector nucleases
- 2016 Tang Prize Laureates Doudna and Charpentier Now Winners of 2020 Nobel Prize in Chemistryon October 7, 2020 at 7:31 am
News broke today (October 7) that 2020 Nobel Prize in Chemistry was jointly awarded to 2016 Tang Prize laureates, Dr. Emmanuelle Charpentier and Dr. Jennifer ...
- 2016 Tang Prize Laureates Doudna and Charpentier Now Winners of 2020 Nobel Prize in Chemistryon October 7, 2020 at 6:23 am
In comparison with the previous gene editing platforms such as TALEN (transcription activator-like effector nuclease) or ZFN (zinc finger nuclease), CRISPR/Cas9 gets the upper hand for being more ...
- Redesigning the Global Food Supplyon October 2, 2020 at 4:19 am
Gene editing technology that harnesses transcription activator-like effector nucleases (TALENs) is being applied by Calyxt, which intends to “enhance the unique characteristics that naturally ...
- Genome Editing Technologies Could Revolutionise Agriculture Finds IDTechEx Reporton September 22, 2020 at 9:03 am
There are currently three main genome editing techniques, zinc finger nucleases (ZFNs), transcription-activator like effector nucleases (TALENs) and the clustered regularly interspaced palindromic ...
- From restriction enzymes to CRISPR-Cas9on January 21, 2018 at 12:49 am
Although there are different methods available for doing this, only a few research laboratories in the world are able to produce customized zinc finger nucleases. Transcription activator-like effector ...